澳大利亚向Wegovy提供补贴,每个脚本25美元,用于治疗有心脏病史的重度肥胖病人。 Australia to subsidize Wegovy to $25 per script for severe obesity patients with heart history.

澳大利亚计划通过其药品福利计划补贴Wegovy,为严重肥胖和心脏病或中风等心血管事件史的人提供每脚本25美元(或特许持有者为7.70美元)的补贴。 Australia plans to subsidize Wegovy through its Pharmaceutical Benefits Scheme, making it available at $25 per script (or $7.70 for concession holders) for people with severe obesity and a history of cardiovascular events like heart attacks or strokes. 这项转移是根据药品福利咨询委员会的建议进行的,目的是减少目前每年5 000美元的类似GLP-1药品费用。 The move follows a recommendation from the Pharmaceutical Benefits Advisory Committee and aims to reduce the current annual cost of up to $5,000 for similar GLP-1 drugs. 卫生部长Mark Butler证实,正与Novo Nordisk进行谈判,以确保公平价格,尽管纳税人的确切费用没有披露。 Health Minister Mark Butler confirmed negotiations with Novo Nordisk are underway to secure a fair price, though the exact cost to taxpayers was not disclosed. 列出清单是为了改善获得保健的机会和解决保健公平问题,而专家们则强调需要包括营养支助在内的全面护理。 The listing is intended to improve access and address health equity, while experts stress the need for comprehensive care including nutrition support. 具体推出日期尚未公布。 A specific rollout date has not been announced.